BSA dosing and suboptimal 5-FU exposure among colorectal cancer patients of varying gender and age.


579 Background: 5-Fluorouracil (5-FU) remains the cornerstone of colorectal cancer (CRC) therapy and its dosing is based on body surface area (BSA). Although convenient, BSA dosing disregards factors that impact 5-FU PK such as genotype, age, gender, etc. Thus, patients receiving the same BSA based dose show a wide range of 5-FU plasma levels (measured as… (More)

1 Figure or Table


  • Presentations referencing similar topics